Somnos Clinical Research | Lincoln, NE

Research site

(Unclaimed)

Location

8040 O. Street, Lincoln, Nebraska, United States of America

Site insights

Top conditions

Top treatments

Rocatinlimab

BHV-7000

TTI-101

AMX0035

AMG 451

Amlitelimab

Empagliflozin

MK-2060

Dupilumab

Finerenone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 20 total trials

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling

Asthma

Drug: Placebo

Drug: Rocatinlimab

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling

Atopic Dermatitis

Drug: Rocatinlimab

Other: Placebo

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures (SHINE)

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-cl...

Enrolling

Generalized Epilepsy

Drug: Placebo

Drug: BHV-7000

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling

Dermatitis Atopic

Drug: Amlitelimab

Drug: Placebo

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting

Chronic Kidney Disease

Type 2 Diabetes Mellitus

Drug: Finerenone (BAY94-8862 ) 20 mg

Drug: Finerenone Placebo

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting

Chronic Spontaneous Urticaria

Drug: LOU064 (blinded)

Drug: Placebo

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting

End-Stage Renal Disease

End-Stage Kidney Disease

Drug: MK-2060

Drug: Placebo

Long-term Safety and Tolerability of BHV-7000

A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy

Invitation-only

Focal Epilepsy

Drug: BHV-7000

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix)

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

Active, not recruiting

Amyotrophic Lateral Sclerosis

Other: Placebo

Drug: AMX0035

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling

Idiopathic Pulmonary Fibrosis

Drug: TTI-101

Drug: Placebo